Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
CAMBRIDGE, Mass., Jan. 27, 2016 -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a leading gene therapy company advancing novel, liver-directed treatments for diverse rare diseases, today announced that Dimension’s Chief Executive Officer Annalisa Jenkins, MBBS, MRCP, and members of the company’s management team will participate in Canaccord Genuity’s 2016 Rare Disease, Biopharma One-on-One Day. The conference is scheduled for Tuesday, February 2, 2016, taking place at the Omni Berkshire Place in New York, NY. Dr. Jenkins and members of the company’s management team also will participate in SunTrust Robinson Humphrey’s 2016 Orphan Drug Day, scheduled for Tuesday, February 23, 2016, and taking place at the JW Marriott Essex House in New York, NY.
About Dimension Therapeutics, Inc.
Dimension Therapeutics, Inc. (NASDAQ:DMTX) is a leading gene therapy company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced, mammalian adeno-associated virus (AAV) delivery technology. The company is rapidly progressing its clinical-stage development pipeline, including programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa, a collaboration with Bayer in hemophilia A, and a wholly owned clinical program in hemophilia B. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts.
For more information, please visit www.dimensiontx.com.
Contacts Burns McClellan, on behalf of Dimension Therapeutics, Inc. Justin Jackson, 212-213-0006, ext. 327 [email protected]
